Skip to main content
SpringerLink
Log in

Assessment of Postmarketing Safety-Related Regulatory Actions in Japan

  • Original Research Article
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Background

Drug agencies and pharmaceutical companies are responsible for continuously monitoring drug safety profiles to implement necessary safety measures. Retrospective analyses of safety-related regulatory actions (SRRAs) are known to be helpful as a tool for evaluating postmarketing safety in Western countries. However, few studies have examined the relationship between SRRAs and postmarketing safety in Japan.

Objective

The aim of this study was to evaluate postmarketing safety risk by examining cases of adverse drug reactions appended to the clinically significant adverse reactions (CSARs) section in package inserts as a marker of Japanese SRRAs.

Methods

We identified new molecular entities (NMEs) approved in Japan between 1 January 1999 and 31 December 2010, and classified them into two groups: NMEs already approved overseas (Overseas group) and NMEs initially or only approved in Japan (Japan group). Each NME included in this study was investigated for CSARs appended into the package insert based on the ‘Revision of Precautions Section of Package Insert’ released by the end of 2011. The potential of exposure to unknown postmarketing safety risk was expressed as the incidence rate of appended CSARs. In addition, the Kaplan-Meier method was used for analysis of the time until the first CSAR was appended.

Results

Among 315 NMEs, we identified 943 appended CSARs that were mandated by the Pharmaceutical and Medical Devices Agency. The incidence rate of CSARs appended for all NMEs was 0.42/drug-year (95% confidence interval [CI] 0.40, 0.45) and individual incidence rates were 0.41/drug-year (95% CI 0.38, 0.44) in the Overseas group, and 0.48/drug-year (95% CI 0.42, 0.55) in the Japan group. In the Overseas group, when subgrouping drugs on the basis of the length of each drug lag, incidence rates of CSARs tended to be greater for shorter drug lags. Using the Overseas group as a reference, the incidence rate ratio (IRR) in the Japan group was evaluated as 1.17 (95% CI 1.01, 1.36). Standardized IRRs for each background factor and the lower limit of the 95% CIs were greater than 1. CSARs were most frequently appended 2 and 3 years after the approval of the NME. Furthermore, CSARs were likely to be appended earlier for NMEs initially or only approved in Japan.

Conclusion

The present results suggest that appended CSARs can offer a useful indicator of Japanese SRRAs. Furthermore, NMEs with little or no foreign safety information are more likely to have unknown safety risks recognized more frequently at an early stage of postmarketing. Although this study focused on Japan, unknown risk generally increases with the elimination of drug lag, regardless of location. Reinforcement of a safety monitoring system is thus vital.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV
Table V
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kleinke JD, Gottlibe S. Is the FDA approving drugs too fast? BMJ 1998; 317: 899

    Article  PubMed  CAS  Google Scholar 

  2. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines. JAMA 1999; 281 (18): 1728–34

    Article  PubMed  CAS  Google Scholar 

  3. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287 (17): 2215–20

    Article  PubMed  Google Scholar 

  4. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008; 358 (13): 1354–61

    Article  PubMed  CAS  Google Scholar 

  5. Nardinelli C, Lanthier M, Temple R. Drug-review deadlines and safety problems. N Engl J Med 2008; 359 (1): 95–6

    Article  PubMed  CAS  Google Scholar 

  6. Olson MK. The risk we bear: the effect of review speed and industry user fees on new drug safety. J Health Economics 2008; 27: 175–200

    Article  Google Scholar 

  7. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and European Union. JAMA 2008; 300 (16): 1887–96

    Article  PubMed  CAS  Google Scholar 

  8. Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for orphan drugs in the US and EU. Drug Saf 2010; 33 (2): 127–37

    Article  PubMed  CAS  Google Scholar 

  9. Mol PG, Straus SM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands. Drug Saf 2010; 33 (6): 463–74

    Article  PubMed  Google Scholar 

  10. Kobayashi D, Kutsuma N, Nakayama M, et al. Current situation of the additional severe adverse effects of marketed medicine [in Japanese]. Jpn J Pharm Health Care Sci 2002; 28 (6): 571–5

    Article  Google Scholar 

  11. Yamada T, Kusama M, Hirai Y, et al. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay? Ann Pharmacother 2010; 44: 1976–85

    Article  PubMed  Google Scholar 

  12. Tsuji K, Tsutani K. Approval of new drugs 1999–2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther 2010; 35: 289–301

    Article  PubMed  CAS  Google Scholar 

  13. Fukuhara H. Period between world first launch and country launch [in Japanese]. Office of Pharmaceutical Research Paper No. 31, May 2006 [online]. Available from URL: http://www.jpma.or.jp/opir/english/06pub31.html [Accessed 2012 Aug 29]

  14. Ministry of Health, Labour and Welfare. Promotion of measures for safety and security of people. In: Annual Health, Labour and Welfare Report 2009–2010, part 2, chapter 2, section 10 [online]. Available from URL: http://www.mhlw.go.jp/english/wp/wp-hw4/dl/honbun/2_2_10.pdf [Accessed 2012 Jul 9]

  15. Tominaga T. Global clinical development: reducing Japan’s drug lags in biotechnology industry. In: Pharma Focus Asia, clinical trials, issue 8 [online]. Available from URL: http://www.pharmafocusasia.com/clinical_trials/global_clinical_development_japan_druglag.htm [Accessed 2012 Jul 9]

  16. Ichimaru K, Toyoshima S, Uyama Y. PMDA’s challenge to accelerate clinical development and review of new drugs in Japan. Clin Pharmacol Ther 2010; 88 (4): 454–7

    Article  PubMed  CAS  Google Scholar 

  17. WHO Collaborating Centre for Drug Statistics Methodology. International language for drug utilization research [online]. Available from URL: http://www.whocc.no/ [Accessed 2012 Aug 30]

  18. PMDA. Information [in Japanese; online]. Available from URL: http://www.info.pmda.go.jp/kaitei/kaitei_index.html [Accessed 2012 Aug 30]

  19. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins, 2008

    Google Scholar 

  20. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24 (3): 233–7

    Article  PubMed  CAS  Google Scholar 

  21. Hartnell NR, Wilson JP, Patel NC, et al. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003; 37: 1387–91

    Article  PubMed  CAS  Google Scholar 

  22. McAdams MA, Governale LA, Swartz L, et al. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf 2008; 17: 882–9

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No funding was provided for this study. Tetsuro Ogami is an employee of Astellas Pharma Inc., Tokyo, Japan. The remaining authors have declared no conflicts of interest. Chieko Ishiguro is affiliated with PMDA, but the views expressed in this article do not necessarily reflect the official views of PMDA.

Author information

Authors and Affiliations

  1. Department of Pharmaceuticals and Medical Devices Regulatory Science, Graduate School of Medical Science, Yamagata University, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japan

    Tetsuro Ogami, Takayuki Imaizumi & Tsutomu Matsuda

  2. Clinical Development III, Development, Astellas Pharma Inc., Tokyo, Japan

    Tetsuro Ogami

  3. Office of Safety I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    Chieko Ishiguro

Authors
  1. Tetsuro Ogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Imaizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chieko Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsutomu Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuro Ogami.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogami, T., Imaizumi, T., Ishiguro, C. et al. Assessment of Postmarketing Safety-Related Regulatory Actions in Japan. Pharm Med 26, 395–403 (2012). https://doi.org/10.1007/BF03262383

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262383

Keywords

Search

Navigation